|Bid||33.83 x 4000|
|Ask||34.03 x 1300|
|Day's Range||33.97 - 34.25|
|52 Week Range||27.59 - 34.31|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.73|
|Expense Ratio (net)||0.70%|
First Trust Advisors L.P. announces the declaration of distributions for 115 exchange-traded funds advised by FTA.
The 13F filings on September 30 indicated that institutional investors own ~87.9% of Stanley Black & Decker’s (SWK) outstanding shares. A total of 817 institutions hold Stanley Black & Decker. Among the institutions, 323 increased their positions on Stanley Black & Decker, 354 reduced their positions, and 140 maintained their positions.
Wall Street analysts expect Sanofi’s (SNY) third-quarter revenues to increase 3.3% to 9.3 billion euros. Sanofi’s stock price has decreased nearly 11.0% over the last 12 months. The stock price has decreased ~1.7% in 2018 year-to-date.
GlaxoSmithKline (GSK) is a leading British multinational pharmaceutical company. It reports its financial results in British pounds and is expected to release its third quarter of 2018 earnings on October 31. The growth drivers for GlaxoSmithKline include new respiratory products and HIV products in the Pharmaceuticals segment.
Novartis’s (NVS) Sandoz is a market leader in differentiated generics. Sandoz reported a 6% decrease in its YoY revenues to ~$2.42 billion during the third quarter of 2018 as compared to $2.58 billion during the third quarter of 2017. The decrease includes a 4% decrease in operating revenues and a 2% negative impact of foreign exchange during the quarter.
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.
Sandoz reported nearly flat revenue of ~$2.46 billion in the second quarter driven by a 2% favorable impact of foreign exchange and offset by a 2% fall in operating revenue in the quarter. The segment’s biopharmaceuticals portfolio reported revenue of $363 million in the second quarter, a 34% rise in operating revenue driven by an increase in US and European sales following the increased demand of the drugs Omnitrope and Zarxio in US markets and Erelzi and Rixathon in European markets.
GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products. During the second quarter of 2018, the Pharmaceutical segment reported a 1% increase in operating revenues to ~4.23 billion pounds.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
First Trust Advisors L.P. (“First Trust”), a global ETF provider and asset manager, announced that Chilean pension funds investment risk rating commission, La Comisión Clasificadora de Riesgo (CCR), has approved an additional First Trust exchange-traded fund (ETF) for sale to Chilean pension funds, known as la Asociación de Administradoras de Fondos de Pensiones (AFPs). According to Chile’s pension plan investment guidelines, before an ETF can be purchased in a pension fund, it must be approved by the CCR.